June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Sickle cell retinopathy:is there a role for follow-up?
Author Affiliations & Notes
  • Beatrice Gallo
    Eye Department, Royal Victoria Infirmary, Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom
  • Francesco Maria D'Alterio
    Eye Department, Royal Victoria Infirmary, Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom
  • Melanie Hall
    Hematology Department, Royal Victoria Infirmary, Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom
  • James Stephen Talks
    Eye Department, Royal Victoria Infirmary, Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom
  • Footnotes
    Commercial Relationships   Beatrice Gallo, None; Francesco D'Alterio, None; Melanie Hall, None; James Talks, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 3180. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Beatrice Gallo, Francesco Maria D'Alterio, Melanie Hall, James Stephen Talks; Sickle cell retinopathy:is there a role for follow-up?. Invest. Ophthalmol. Vis. Sci. 2021;62(8):3180.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The role of regular ophthalmic screening in patients with sickle cell retinopathy is controversial and there are no studies guiding the frequency of review,hence the scope of this study.

Methods : Retrospective observational study of 66 eyes of 33 patients (20 females, median age 30 years, age range 17-60 years) with sickle cell disease screened for retinopathy with fundoscopy,ultrawide-field pseudocolour fundus pictures (Optos plc, Dunfermline, UK) and OCT-angiography. Type and progression of retinal findings were recorded at each visit.

Results : 25 patients had SS (sickle cell anemia) and 8 patients had SC (sickle cell/hemoglobin C compound). Ethnicity was African in 21 patients, Caribbean in 8 patients, Asian in 2 patients and Caucasian in 2 patients. 9 patients were on systemic treatment (8 hydroxycarbamide, 1 blood transfusions), 24 were not on treatment (1 received allogenic transplant), 6 of whom refused treatment. Median follow-up duration was 18 months (range 0-47 months) and median number of visits was 2. Retinopathy was observed in 39 eyes (unilateral in 7 patients and bilateral in 16 patients). Retinal abnormalities included peripheral vascular closure (24 eyes, 15 patients), black sunbursts (17 eyes, 13 patients), sea-fan neovascularization (9 eyes, 5 patients) (Figure 1) and pale retinal patches (5 eyes, 3 patients). At baseline, there was no statistically significative difference in the distribution of the retinal abnormalities according to disease subtype (p>0.05) and according to treatment group. Over the follow-up period, retinopathy progression was observed in 4 eyes from 2 patients (6,3%) affected by SS who refused systemic treatment. Progression consisted in new retinal hemorrhages (1 eye), new sea-fans (1 eye) or fibrosis enlargement (2 eyes), and was not vision threatening. In 4 eyes from 2 SS patients the OCT-A showed foveal avascular zone enlargement and superficial and deep capillary plexus drop-out (Figure 2).

Conclusions : No correlation was found between disease subtype and retinal abnormalities. Progression of retinopathy was detected in a small number of patients refusing systemic treatment that should be considered.Given the low rate of progression, a low frequency in monitoring sickle cell retinopathy would be adequate. Studies on larger cohort of patients are needed to confirm our clinical impression.

This is a 2021 ARVO Annual Meeting abstract.

 

Figure 1: Fundus pictures of a SC patient.

Figure 1: Fundus pictures of a SC patient.

 

Figure 2: OCT-A SCP and DCP of RE and DCP of LE of a SS patient.

Figure 2: OCT-A SCP and DCP of RE and DCP of LE of a SS patient.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×